Study S002364

Effect of Exenatide Treatment on Hepatic Fat Content and Plasma Adipocytokine Levels in Patients With Type 2 Diabetes Mellitus

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT01432405
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: COMPLETED
Enrollment: 24
Start: 2007-06
Primary completion: 2008-07
Lead sponsor: Baylor College of Medicine
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG:Exenatide; DRUG:Pioglitazone
Results posted: TRUE

Registered primary outcomes

Hepatic Fat [one year]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0022834	Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial. Samson SL, Diabetologia	2011	Randomized trial	PMID 21956711 DOI	cites ClinicalTrials.gov:NCT01432405; registry reference DERIVED:21956711